跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
XIIDRA - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
XIIDRA
Authorized
STANDARD
XIIDRA
bausch & lomb inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
a1c0df3bde27fbca
Company
bausch & lomb inc
Type
Standard
Approval Details
Approval Id
a1c0df3bde27fbca
Drug Approval Canada Name
XIIDRA
Product Name
XIIDRA
Status
Marketed
Status Date
2024-08-20
Original Market Date
2018-02-12
Din
02471027
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Ophthalmic
Schedule
Prescription
Ahfs
52:08.00
Atc Original
S01XA25 LIFITEGRAST
Atc Name
s 01 xa 25
Aig Number
0159830001
Company Name
bausch & lomb inc
Company Address
1400 N Goodman Street, Rochester, New York, United States, 14609
Active Ingredients
LIFITEGRAST
5 % / W/V
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
a1c0df3bde27fbca
Type
Standard
Back to Health Canada Approvals